REGENXBIO: Gene‑Therapy Pioneer Facing Volatility & Bold Growth
Discover how REGENXBIO is reshaping gene therapy for genetic disorders, its biotech stock trends, and future market potential.
3 minutes to read
REGENXBIO Inc
REGENXBIO Inc. Advances Gene Therapy for Duchenne Muscular Dystrophy, Eyes 2026 BLA Submission
REGENXBIO Inc. has made significant progress in its gene therapy pipeline, with several promising therapies in development and a potential BLA submission for Duchenne muscular dystrophy treatment by mid-2026.
2 minutes to read
REGENXBIO Inc. to Showcase Gene Therapy Innovations at Key Investor Conferences in 2025
REGENXBIO Inc. is set to participate in several investor conferences in May 2025, showcasing its innovative pipeline and gene therapy innovations, and positioning itself for growth in the rapidly evolving biotechnology sector.
3 minutes to read